From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Factors Preventing Exogenous Insulin Therapy in LADA
- Delay in insulin therapy due to lack of recommendations for islet antibody testing in adult-onset diabetes 1
- Use of sulfonylureas, which can exhaust β-cells and lead to earlier insulin dependence 2
- Heterogeneity of LADA, making it difficult to establish a priori treatment algorithm and resulting in treatment as type 2 diabetes, which may lead to quick progression to insulin-dependency 3
- Limited understanding of the disease, with no specific guidelines for LADA therapy available 3, 4
- Variability in β-cell destruction, insulin resistance, and islet autoantibody titers, suggesting different pathophysiological pathways and making treatment challenging 3
Treatment Challenges in LADA
- Lack of significant evidence for or against specific lines of treatment, except for the indication that sulfonylureas should not be a first-line treatment for antibody-positive type 2 diabetes 2
- Need for personalized medicine approach to attain optimal metabolic control and preserve β-cell function 3
- Importance of early insulin therapy to achieve good metabolic control and better long-term outcomes by preserving β-cells and endogenous C-peptide secretion 1, 5